Assessing predictors of drug-induced torsade de pointes

Trends in Pharmacological Sciences

Volumn 24, Issue 12, 2003, Pages 619-625

  Belardinelli, Luiz ^a   Antzelevitch, Charles ^b   Vos, Marc A ^c  

^a CV THERAPEUTICS INC   (United States)

^b MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ALMOKALANT; AMIODARONE; ANTHOPLEURIN A; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ASTEMIZOLE; AZIMILIDE; AZITHROMYCIN; BAYK 8644; BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; CARBOXYLIC ACID DERIVATIVE; CISAPRIDE; CLARITHROMYCIN; DILTIAZEM; DOFETILIDE; DRONEDARONE; DROPERIDOL; DRUG; ERYTHROMYCIN; FLUOXETINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IBUTILIDE; KETANSERIN; METHYL 4 [2 (TRIFLUOROMETHYL)PHENYL] 1,4 DIHYDRO 2 METHYL 5 NITRO 6 PHENYLPYRIDINE 3 CARBOXYLATE; MIBEFRADIL; NEUROLEPTIC AGENT; PENTOBARBITAL; QUINIDINE; SEA ANEMONE TOXIN; SERTINDOLE; SOTALOL; TERFENADINE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL; CELL ASSAY; DISEASE COURSE; DRUG INDUCED DISEASE; ELECTROPHYSIOLOGY; EXTRASYSTOLE; HEART DEPOLARIZATION; HEART MUSCLE POTENTIAL; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IATROGENIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; REENTRY TACHYCARDIA; REVIEW; TORSADE DES POINTES;

EID: 0344688172     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2003.10.002     Document Type: Review

References (59)

1. Curtis L.H., et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am. J. Med. 114:2003;135-141.
2. Haverkamp W., et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Cardiovasc. Res. 47:2000;219-233.
3. Tamargo J. Drug-induced torsade de pointes: from molecular biology to bedside. Jpn. J. Pharmacol. 83:2000;1-19.
4. Yap Y.G., Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. BMJ. 320:2000;1158-1159.
5. Redfern W.S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58:2003;32-45.
6. van Opstal J.M., et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 104:2001a;2722-2727.
7. Vos M.A., et al. Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsades de Pointes arrhythmias. Pharmacol. Ther. 92:2001;109-122.
8. Vos M.A. Do we understand the electrophysiological mechanisms responsible for drug-induced cardiac arrhythmias? J. Cardiovasc. Pharmacol. 40:2002;647-650.
9. Janse M.J., Downar E. Reentry. Spooner P.M., Rosen M.R. Foundations of Cardiac Arrhythmias: Basic Concepts and Clinical Approaches. 2001;449-477 Marcel Dekker.
10. Dumaine, R. and Antzelevitch, C. (2002) Electrical heterogeneity in the heart: physiological, pharmacological, and clinical implications. In Handbook of Physiology (Page, Fozzard, and Solaro, eds), pp. 654-692, Oxford University Press.
11. Diego, J.M., et al. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge during epicardial stimulation. Circulation (in press).
12. Verduyn S.C., et al. Role of interventricular dispersion of repolarization in acquired Torsades de Pointes arrythmias: reversal by magnesium. Cardiovasc. Res. 34:1997a;453-463.
13. Verduyn S.C., et al. Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired torsade de pointes arrhythmias: a comparison between almokalant and d-sotalol using the dog as its own control. J. Am. Coll. Cardiol. 30:1997b;1575-1584.
14. van Opstal J.M., et al. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias. Eur. J. Pharmacol. 412:2001b;67-76.
15. Antzelevitch C., Shimizu W. Cellular mechanisms underlying long QT syndrome. Curr. Opin. Cardiol. 17:2002;43-51.
16. Eckhardt L., et al. Electrophysiologic characterization of the antipsychotic drug sertinadole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. J. Pharmacol. Exp. Ther. 300:2002;64-71.
17. Yan G.-X., et al. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome. Direct evidence from intracellular recordings in the intact left ventricular wall. Circulation. 103:2001;2851-2856.
18. Surawicz B. Contributions of cellular electrophysiology to the understanding of the electrocardiogram. Experientia. 43:1987;1061-1068.
19. Luo C.-H., Rudy Y. A model of the cardiac ventricular action potential: depolarization, repolarization, and their interaction. Circ. Res. 68:1991;1501-1526.
20. Luo C.-H., Rudy Y. A dynamic model of the ventricular cardiac action potential. I. Simulations of ionic currents and concentration changes. Circ. Res. 74:1994;1071-1096.
21. Volders P.G.A., et al. Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc. Res. 46:2000;376-392.
22. Milberg P., et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J. Pharmacol. Exp. Ther. 303:2002;218-225.
23. Hondeghem L.M., et al. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc. Res. 50:2001a;345-353.
24. Hondeghem L.M., et al. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation. 103:2001b;2004-2013.
25. Cranefield P.F. Action potentials, afterpotentials, and arrhythmias. Circ. Res. 41:1977;415-423.
26. Luo C.-H., Rudy Y. A dynamic model of the ventricular cardiac action potential. II. Afterdepolarizations, triggered activity, and potentiation. Circ. Res. 74:1994b;1097-1113.
27. Viswanathan P.C., Rudy Y. Pause induced early afterdepolarizations in the long QY syndrome: a simulation study. Cardiovasc. Res. 42:1999;530-542.
28. Sicouri S., Antzelevitch C. Drug-induced afterdepolarizations and triggered activity occur in a discrete subpopulation of ventricular muscle cells (M cells) in the canine heart: quinidine and digitalis. J. Cardiovasc. Electrophysiol. 4:1993;48-58.
29. + current. Circ. Res. 64:1989;977-990.
30. El-Sherif N., et al. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome: tridimensional mapping of activation and recovery patterns. Circ. Res. 79:1996;474-492.
31. Yan G.-X., Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long QT syndrome. Circulation. 98:1998;1928-1936.
32. Antzelevitch C., et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J. Cardiovasc. Electrophysiol. 10:1999;1124-1152.
33. Asano Y., et al. Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart. J. Am. Coll. Cardiol. 29:1997;831-842.
34. D'Alnoncourt C.N., et al. Torsades de Pointes tachycardia: reentry or focal activity? Br. Heart J. 48:1982;213-216.
35. Senges J.C., et al. Cesium chloride induced ventricular arrhythmias in dogs: three-dimensional activation patterns and their relation to the cesium dose applied. Basic Res. Cardiol. 95:2000;152-162.
36. Murakawa Y., et al. Three-dimensional activation sequence of cesium-induced ventricular arrhythmias. Am. J. Physiol. 273:1997;H1377-H1385.
37. Surawicz B. Electrophysiologic substrate of torsades de pointes: dispersion of repolarization or early afterdepolarizations? J. Am. Coll. Cardiol. 14:1989;172-184.
38. Surawicz B. Torsades de pointes: unanswered questions. J. Nippon Med. Sch. 69:2002;218-223.
39. Jackman W.M., et al. The long QT syndromes: a critical review, new clinical observations and unifying hypothesis. Prog. Cardiovasc. Dis. 31:1988;115-172.
40. Carlsson L., et al. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarizations. Cardiovasc. Res. 27:1993;2186-2193.
41. El-Sherif N., Turitto G. Torsade de Pointes. Zipes D.P., Jalife J. Cardiac Electrophysiology: From Cell to Bedside. 3rd edn: 2000;662-673 WB Saunders & Co.
42. Jungschleger J.G.M., et al. No dominant role for re-entry in the perpetuation of drug induced torsades de pointes arrhythmias in the CAVB dog. Pacing Clin. Electrophysiol. 24:2002;627. Abstr.
43. Akar F.G., et al. Cellular basis for dispersion of repolarization underlying reentrant arrhythmias. J. Electrocardiol. 33:2000;23-31.
44. Hii J.T.Y., et al. Precordial QT interval dispersion as a maker of torsade de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation. 86:1992;1376-1382.
45. Priori S.G., et al. Dispersion of the QT interval: a marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation. 89:1994;1681-1689.
46. Houltz B., et al. Electrocardiographic and clinical predictors of torsade de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin. Electrophysiol. 21:1998;1044-1057.
47. Lubinski A., et al. New insight into repolarization abnormalities in patients with congenital long QT syndrome: the increased transmural dispersion of repolarization. Pacing Clin. Electrophysiol. 21:1998;172-175.
48. Vos M.A., et al. Enhanced susceptibility for acquired torsades de pointes arrhythmias in the dog with chronic, complete AVblock is related to cardiac hypertrophy and electrical remodeling. Circulation. 98:1998;1125-1135.
49. Antzelevitch C., et al. Electrical heterogeneity, the ECG, and cardiac arrhythmias. Zipes D.P., Jalife J. Cardiac Electrophysiology: From Cell to Bedside. 3rd edn: 2000;222-238 WP Saunders Company.
50. Day C.P., et al. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br. Heart J. 63:1990;342-344.
51. Shimizu W., et al. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de pointes in models of acquired and congenital long QT syndrome. J. Cardiovasc. Electrophysiol. 10:1999;154-164.
52. Hohnloser S.H., et al. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann. Intern. Med. 121:1994;529-535.
53. Splawski I., et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science. 297:2002;1333-1336.
54. Makita N., et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation. 106:2002;1269-1274.
55. El-Sherif N., et al. Dose-dependent modulation of the cardiac sodium channel by sea anemone toxin ATXII. Circ. Res. 70:1992;285-301.
56. + current: differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 96:1990;195-215.
57. Sun Z.-Q., et al. Chromanol 293B inhibits slowly activating delayed rectifier and transient outward currents in canine left ventricular myocytes. J. Cardiovasc. Electrophysiol. 12:2001;472-478.
58. Song, Y., et al. (2003) Sodium channel dysfunction predisposes cardiac myocytes to potassium channel blocker-induced early afterdepolarizations. Pacing Clin. Electrophysiol 26, 993 (Abstr.).
59. Hondeghem L.M., Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration, prolongation, and proarrhythemic drugs: importance of triangulation, reverse use dependence, and instability. J. Cardiovasc. Pharmacol. 41:2003;14-24.